Drug intelligence / Profile preview

Acacia ferruginea extract

Development stage: Preclinical
Administration: Oral, Intraperitoneal For Research Purposes

Overview

Acacia ferruginea extract is derived from the plant *Acacia ferruginea*, which is traditionally used for its medicinal properties. It contains bioactive compounds such as flavonoids, tannins, phenolic acids, saponins, and alkaloids. The extract has been studied for its anti-inflammatory, antioxidant, anti-hemorrhoidal, nephroprotective, anti-diabetic, and anti-hyperlipidemic activities.

Targets

NOS2 (Nitric Oxide Synthase 2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NF-κB

Beyond the preview

Go deeper on Acacia ferruginea extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acacia ferruginea extract.

Explore the full profile